New drug combo aims to free CML patients from lifelong pills after failed first try
NCT ID NCT03610971
Summary
This study is for people with chronic myeloid leukemia (CML) who had to restart their daily pills after trying to stop them once. Researchers want to see if adding a drug called ruxolitinib to their current CML medication for a year can help them successfully stop all treatment for a longer period the second time they try. The trial will follow 24 participants for about four years to measure how many remain in remission without needing their CML drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC PHASE CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
David H. Koch Center for Cancer Care at Memorial Sloan Kettering
New York, New York, 10021, United States
-
Duke University Hospital
Durham, North Carolina, 27710, United States
-
Emory -Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Memorial Sloan Kettering - Bergen
Montvale, New Jersey, 07645, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.